期刊文献+

Antiplatelet aggregation activity of some ferrocenylphenylimine compounds

Antiplatelet aggregation activity of some ferrocenylphenylimine compounds
原文传递
导出
摘要 Platelet hyper-aggregability triggered death and disability due to cardiovascular diseases is increasing worldwide and becoming a global concern. Therefore, it is necessary to synthesize newer drugs for the management of platelet aggregation. In this study, we investigated the antiplatelet aggregation activity of a novel series of ferrocenylimine compounds(3–10), N-(3-nitro-2-hydroxylbenzylidene)-3-ferrocenylimine(3), N-(3-bromo-2-hydroxylbenzylidene)-3-ferrocenylimine(4), N-(3-bromo-5-chlorosalicylidene)-3-ferrocenylimine(5), N-(ferrocenylformidene)-3-ferrocenylimine(6), N-(3-nitro-2-hydroxylbenzylidene)-4-ferrocenylimine(7), N-(3-bromo-2-hydroxylbenzylidene)-4-ferrocenylimine(8), N-(3-bromo-5-chlorosalicyl)-4-ferrocenylimine(9), N-(ferrocenylformidene)-4-ferrocenylimine(10) on thrombin-and ADP-induced platelet aggregation. The synthesized ferrocenylimine compounds(3–10) were found to exhibit higher antiplatelet aggregation activity than their precursors, which are 3-ferrocenylaniline(compound 1) and 4-ferrocenylaniline(compound 2). Among the derivatives, compounds 5, 6 and 10 possessed excellent platelet aggregation inhibition against the agonists. Platelet hyper-aggregability triggered death and disability due to cardiovascular diseases is increasing worldwide and becoming a global concern. Therefore, it is necessary to synthesize newer drugs for the management of platelet aggregation. In this study, we investigated the antiplatelet aggregation activity of a novel series of ferrocenylimine compounds (3-10), N-(3-nitro-2- hydroxylbenzylidene)-3-ferrocenylimine 0), N-(3-bromo-2-hydroxylbenzylidene)-3-ferrocenylimine (4), N-(3-bromo-5-chlorosalicylidene)- 3-ferrocenylimine (5), N-(ferrocenylformidene)-3-ferrocenylimine (6), N-(3-nitro-2-hydroxylbenzylidene)-4-ferrocenylimine (7), N-(3-bromo-2-hydroxylbenzylidene)-4-ferrocenylimine (8), N-(3-bromo-5-chlorosalicyl)-4-ferrocenylimine (9), N-(ferrocenylformidene)- 4-ferrocenylimine (10) on thrombin- and ADP-induced platelet aggregation. The synthesized ferrocenylimine compounds (3-10) were found to exhibit higher antiplatelet aggregation activity than their precursors, which are 3-ferrocenylaniline (compound 1) and 4-ferrocenylaniline (compound 2). Among the derivatives, compounds 5, 6 and 10 possessed excellent platelet aggregation inhibition against the agonists.
出处 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2017年第6期460-464,共5页 中国药学(英文版)
基金 Global Excellence and Stature(GES),2016,University of Johannesburg
关键词 FERROCENE IMINE Antiplatelet aggregation THROMBIN PLATELET Ferrocene Imine Antiplatelet aggregation Thrombin Platelet
  • 相关文献

参考文献1

二级参考文献45

  • 1Coleman K S, Turberville S, Pascu S I, et al. J. Organomet. Chem., 2005,690:653-658.
  • 2Ikhile M I, Bala M D, Nyamori V O, et al. Appl. Organometal. Chem., 2013,27:98-108.
  • 3Togni A, Hayashi T (Eds.) Ferrocenes:Homogeneous Catalysis, Organic Synthesis and Material Science. Weinheim:VCH, 1995.
  • 4Diallo A K, Ornelas C, Salmon L, et al. Chem. Commun., 2007:4946-4948.
  • 5Nazarov A A, Hartinger C. G, Arion V B, et al. Tetrahedron, 2002,58:8489.
  • 6Gibson V C, Gregson C K A, Halliwell C M, et al. Organomet. Chem., 2004,690:6271-6283.
  • 7Andrieux C P, Blocman C, Dumas-Bouchiat J M, et al. J. Am. Chem. Soc., 1980,102:3806-3813.
  • 8Ferreira C L, Ewart C B, Barta C A, et al. Inorg. Chem., 2006,45:8414-8422.
  • 9Mishra L, Dubey S K. Spectrochim. Acta A, 2007,68:364-368.
  • 10Bildstein B, Malaun M, Kopacka H, et al. J. Organomet. Chem., 1999,572:177-187.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部